Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
Ceclor	O
/	O
Keflex	O
/	O
prednisone	O
/	O
sulfamethoxazole	O
/	O
furin	O
/	O
methyl	O
/	O
cephalus	O
Attending:	O
___.	O
Chief	O
Complaint:	O
pancreatic	O
mass,	O
weight	B-Weight_loss
loss	B-Weight_loss
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
ERCP	O
s/p	O
pancreatic	O
duct	O
brushings,	O
pancreatic	O
duct	O
stent	O
placement,	O
pancreatic	O
sphincterotomy	O
History	O
of	O
Present	O
Illness:	O
This	O
is	O
a	O
___	O
y/o	O
man	O
with	O
a	O
medical	O
history	O
notable	O
for	O
HTN,	O
HL,	O
hemorrhagic	O
CVA	O
___	O
s/p	O
VP	O
shunt,	O
admitted	O
for	O
monitoring	O
post	O
ERCP	O
for	O
a	O
pancreatic	O
mass.	O
Patient	O
initially	O
had	O
symptoms	O
beginning	O
in	O
late	O
___	O
of	O
sharp	O
abdominal	O
pain	O
and	O
back	O
pain.	O
He	O
also	O
began	O
having	O
post-prandial	O
diarrhea	O
along	O
with	O
a	O
40-lb	O
unintentional	O
weight	B-Weight_loss
loss	B-Weight_loss
since	O
the	O
end	O
of	O
___.	O
He	O
initially	O
saw	O
his	O
PCP	O
and	O
___	O
local	O
specialist,	O
who	O
diagnosed	O
him	O
with	O
IBS	O
and	O
started	O
him	O
on	O
dicyclomine.	O
Due	O
to	O
persistent	O
symptoms	O
and	O
further	O
weight	B-Weight_loss
loss,	B-Weight_loss
he	O
was	O
referred	O
to	O
___	O
for	O
further	O
work-up.	O
He	O
denies	O
any	O
symptoms	O
f/c/s,	O
jaundice,	O
acholic	O
stools	O
or	O
changes	O
to	O
his	O
urine	O
at	O
that	O
time.	O
He	O
underwent	O
an	O
EUS	O
on	O
___	O
which	O
demonstrated	O
2x3	O
cm	O
mass	O
in	O
the	O
HOP	O
with	O
dilatation	O
of	O
the	O
main	O
PD.	O
An	O
FNA	O
was	O
done	O
and	O
came	O
back	O
as	O
cystic	O
neoplasm	O
vs.	O
GI	O
contamination.	O
Therefore,	O
he	O
was	O
brought	O
back	O
for	O
an	O
ERCP	O
today	O
which	O
he	O
underwent	O
without	O
any	O
immediate	O
complications.	O
Brushings	O
of	O
the	O
PD,	O
stent	O
insertion	O
into	O
the	O
PD	O
and	O
a	O
PD	O
sphincterotomy	O
were	O
performed.	O
He	O
did	O
have	O
left-sided	O
CP	O
post-procedure,	O
which	O
he	O
described	O
as	O
sharp	O
and	O
15	O
minutes	O
in	O
duration	O
(currently	O
pain	O
free).	O
EKG	O
at	O
the	O
time	O
was	O
without	O
signs	O
of	O
ischemic	O
changes.	O
Currently	O
the	O
patient	O
is	O
without	O
CP,	O
but	O
reports	O
___	O
abd	O
pain	O
and	O
abd	O
bloating/distenstion.	O
No	O
n/v.	O
No	O
f/c/s.	O
No	O
other	O
new	O
symptoms.	O
12-pt	O
ROS	O
otherwise	O
negative	O
except	O
for	O
as	O
described	O
above.	O
Past	O
Medical	O
History:	O
HTN	O
Hyperlipidemia	O
Hemorrhagic	O
CVA	O
s/p	O
VP	O
shunt	O
(residual	O
memory	O
loss)	O
Headaches	O
(due	O
to	O
increased	O
ICP)	O
Social	O
History:	O
___	O
Family	O
History:	O
Maternal	O
uncle	O
with	O
pancreatic	O
cancer	O
Physical	O
Exam:	O
VS:	O
Tc	O
97.8,	O
BP	O
158/81,	O
HR	O
59,	O
RR	O
18,	O
SaO2	O
100/RA	O
General:	O
Older	O
man	O
in	O
NAD,	O
AO	B-Delirium
x	O
3	O
HEENT:	O
Anicteric	O
sclerae,	O
MM	O
dry,	O
OP	O
clear	O
Neck:	O
supple,	O
no	O
LAD	O
Chest:	O
CTA-B,	O
no	O
w/r/r	O
CV:	O
RRR	O
s1	O
s2	O
normal,	O
no	O
m/g/r	O
Abd:	O
soft,	O
distended	O
with	O
NABS,	O
slight	O
TTP	O
over	O
epigastric	O
area,	O
no	O
peritoneal	O
signs	O
Ext:	O
no	O
c/c/e	O
Skin:	O
warm,	O
dry,	O
no	O
jaundice	O
Pertinent	O
Results:	O
___	O
12:50PM	O
WBC-4.8	O
RBC-4.11*	O
HGB-11.7*	O
HCT-37.0*	O
MCV-90	O
MCH-28.5	O
MCHC-31.6*	O
RDW-14.5	O
RDWSD-47.8*	O
___	O
12:50PM	O
PLT	O
COUNT-128*	O
___	O
12:50PM	O
___	O
PTT-34.7	O
___	O
___	O
12:50PM	O
LIPASE-6	O
___	O
12:50PM	O
ALT(SGPT)-66*	O
AST(SGOT)-65*	O
ALK	O
PHOS-333*	O
AMYLASE-52	O
TOT	O
BILI-0.3	O
___	O
12:50PM	O
UREA	O
N-14	O
CREAT-1.2	O
SODIUM-142	O
POTASSIUM-3.9	O
CHLORIDE-112*	O
TOTAL	O
CO2-19*	O
ANION	O
GAP-15	O
___	O
04:00PM	O
CK(CPK)-86	O
___	O
06:00AM	O
BLOOD	O
WBC-3.6*	O
RBC-4.01*	O
Hgb-11.5*	O
Hct-36.0*	O
MCV-90	O
MCH-28.7	O
MCHC-31.9*	O
RDW-14.4	O
RDWSD-47.1*	O
Plt	O
___	O
___	O
06:00AM	O
BLOOD	O
Glucose-66*	O
UreaN-13	O
Creat-1.1	O
Na-142	O
K-4.0	O
Cl-110*	O
HCO3-21*	O
AnGap-15	O
___	O
06:00AM	O
BLOOD	O
ALT-209*	O
AST-282*	O
AlkPhos-464*	O
TotBili-1.9*	O
___	O
04:00PM	O
BLOOD	O
cTropnT-<0.01	O
___	O
12:50PM	O
BLOOD	O
___	O
EKG:	O
sinus	O
brady,	O
slight	O
sinus	O
arrhythmia,	O
no	O
ST	O
or	O
T	O
wave	O
changes	O
___	O
ERCP:	O
There	O
was	O
evidence	O
of	O
narrowing	O
at	O
D1/D2.	O
The	O
duodenoscope	O
was	O
removed	O
and	O
a	O
gastroscope	O
was	O
advanced	O
to	O
this	O
level.	O
A	O
CRE	O
balloon	O
catheter	O
was	O
inserted	O
through	O
the	O
gastroscope	O
and	O
the	O
area	O
of	O
narrowing	O
was	O
dilated	O
from	O
12	O
to	O
15	O
mm.	O
The	O
duodenoscope	O
was	O
reinserted.	O
A	O
bulging,	O
edematous	O
and	O
distorted	O
papilla	O
was	O
noted.	O
Given	O
a	O
tight	O
stricture	O
at	O
the	O
level	O
of	O
the	O
intra-ampullary	O
segment	O
of	O
the	O
pancreatic	O
duct	O
we	O
were	O
unable	O
to	O
cannulate	O
with	O
a	O
sphincterotome.	O
Cannulation	O
of	O
the	O
pancreatic	O
duct	O
was	O
successful	O
and	O
deep	O
with	O
a	O
___	O
cannula	O
using	O
a	O
free-hand	O
technique.	O
Contrast	O
medium	O
was	O
injected	O
resulting	O
in	O
complete	O
opacification.	O
The	O
procedure	O
was	O
moderately	O
difficult.	O
The	O
pancreatic	O
duct	O
was	O
filled	O
with	O
contrast	O
and	O
well	O
visualized	O
throughout.	O
There	O
was	O
evidence	O
of	O
a	O
1cm	O
stricture	O
of	O
the	O
intra-ampullary	O
segment	O
of	O
the	O
pancreatic	O
duct.	O
The	O
remainder	O
of	O
the	O
pancreatic	O
duct	O
was	O
dilated	O
to	O
11	O
mm.	O
A	O
7cm	O
by	O
___	O
single	O
pigtail	O
pancreatic	O
stent	O
was	O
placed	O
successfully.	O
A	O
pancreatic	O
sphincterotomy	O
was	O
performed	O
in	O
the	O
12	O
o'clock	O
position	O
using	O
a	O
needle-knife.	O
There	O
was	O
evidence	O
of	O
mild	O
oozing.	O
A	O
total	O
of	O
7	O
mL	O
of	O
1:10,000	O
Epinephrine	O
was	O
injected	O
with	O
good	O
effect.	O
Cytology	O
samples	O
of	O
the	O
pancreatic	O
duct	O
stricture	O
were	O
obtained	O
for	O
histology	O
using	O
a	O
brush.	O
Cold	O
forceps	O
biopsies	O
of	O
the	O
ampulla	O
were	O
taken	O
and	O
were	O
sent	O
for	O
histology.	O
Brief	O
Hospital	O
Course:	O
Assessment	O
-	O
___	O
y/o	O
man	O
with	O
unintentional	O
weight	B-Weight_loss
loss,	B-Weight_loss
abd	O
pain,	O
diarrhea	O
x	O
6	O
months,	O
presenting	O
for	O
further	O
evaluation	O
of	O
a	O
pancreatic	O
mass	O
concerning	O
for	O
malignancy,	O
now	O
s/p	O
ERCP.	O
#	O
Pancreatic	O
mass:	O
s/p	O
ERCP	O
which	O
revealed	O
bulging	O
papilla,	O
narrowing	O
of	O
first	O
two	O
segments	O
of	O
duodenum	O
and	O
stricture	O
in	O
the	O
pancreatic	O
duct.	O
Pancreatic	O
brushings	O
sent	O
for	O
cytology,	O
also	O
underwent	O
pancreatic	O
duct	O
stent	O
placement	O
and	O
pancreatic	O
sphincterotomy.	O
He	O
tolerated	O
the	O
procedure	O
well,	O
but	O
had	O
an	O
elevation	O
in	O
his	O
transaminases	O
and	O
bilirubin	O
post-procedure.	O
On	O
day	O
of	O
discharge	O
labs	O
worsened	O
slightly	O
(with	O
increase	O
in	O
bilirubin).	O
Pt	O
declined	O
to	O
stay	O
an	O
additional	O
day.	O
MRCP	O
was	O
attempted	O
but	O
pt	O
was	O
unable	O
to	O
tolerate.	O
There	O
was	O
discussion	O
about	O
whether	O
to	O
pursue	O
CT	O
pancreatic	O
protocol,	O
but	O
Dr.	O
___	O
radiology	O
discussed,	O
and	O
decision	O
was	O
made	O
to	O
hold	O
off	O
on	O
further	O
imaging	O
until	O
cytology	O
results	O
return.	O
-	O
brushing	O
samples	O
from	O
pancreatic	O
duct	O
are	O
pending	O
-	O
He	O
will	O
need	O
to	O
return	O
in	O
3	O
weeks	O
for	O
removal	O
of	O
the	O
stent	O
-	O
will	O
need	O
to	O
take	O
5	O
days	O
cipro	O
-	O
will	O
need	O
to	O
have	O
labs	O
rechecked	O
#Abdominal	O
pain	O
-	O
likely	O
related	O
to	O
pancreatic	O
mass,	O
appears	O
to	O
have	O
responded	O
to	O
tramadol	O
prn	O
#	O
Chest	O
pain:	O
Patient	O
experienced	O
some	O
chest	O
pain	O
after	O
the	O
procedure	O
and	O
had	O
an	O
EKG	O
thet	O
was	O
negative	O
for	O
ischemic	O
changes	O
and	O
a	O
troponin	O
level	O
that	O
was	O
negative	O
#	O
HTN:	O
Cardizem	O
CD	O
continued	O
until	O
pt	O
ran	O
out	O
of	O
his	O
own	O
pill	O
supply	O
(reports	O
he	O
cannot	O
do	O
generic	O
due	O
to	O
allergy).	O
He	O
was	O
given	O
metoprolol	O
in-house	O
thereafter,	O
but	O
will	O
resume	O
Cardizem	O
CD	O
upon	O
discharge.	O
#	O
Mood	O
disorder,	O
NOS:	O
Continue	O
celexa	O
and	O
Topamax	O
#	O
hx	O
VP	O
shunt	O
for	O
hx	O
hemorrhagic	O
CVA	O
-	O
seen	O
by	O
neurosurgery	O
after	O
his	O
MRCP	O
to	O
re-calibrate	O
his	O
VP	O
shunt.	O
#	O
Mild	O
thrombocytopenia:	O
Patient	O
without	O
signs	O
of	O
bleeding	O
but	O
he	O
developed	O
some	O
petecheie	O
at	O
the	O
site	O
of	O
a	O
blood	O
draw.	O
Unclear	O
if	O
thrombocytopenia	O
is	O
old	O
or	O
new.	O
Remained	O
stable	O
in-house	O
in	O
the	O
low	O
100s.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
butalbital-acetaminophen-caff	O
50-300-40	O
mg	O
oral	O
DAILY:PRN	O
migraine	O
2.	O
Citalopram	O
40	O
mg	O
PO	O
DAILY	O
3.	O
DICYCLOMine	O
20	O
mg	O
PO	O
DAILY	O
4.	O
Cardizem	O
CD	O
120	O
mg	O
oral	O
DAILY	O
5.	O
Mirtazapine	O
30	O
mg	O
PO	O
QHS	O
6.	O
Simvastatin	O
Dose	O
is	O
Unknown	O
PO	O
DAILY	O
7.	O
Topiramate	O
(Topamax)	O
50	O
mg	O
PO	O
QID	O
Discharge	O
Medications:	O
1.	O
Cardizem	O
CD	O
120	O
mg	O
oral	O
DAILY	O
2.	O
Citalopram	O
40	O
mg	O
PO	O
DAILY	O
3.	O
Mirtazapine	O
30	O
mg	O
PO	O
QHS	O
4.	O
Topiramate	O
(Topamax)	O
100	O
mg	O
PO	O
BID	O
5.	O
DICYCLOMine	O
20	O
mg	O
PO	O
DAILY	O
6.	O
butalbital-acetaminophen-caff	O
50-300-40	O
mg	O
oral	O
DAILY:PRN	O
migraine	O
7.	O
TraMADol	O
50	O
mg	O
PO	O
Q6H:PRN	O
abdominal	O
pain	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
1.	O
Pancreatic	O
mass	O
2.	O
Abdominal	O
Pain	O
3.	O
VP	O
shunt	O
Discharge	O
Condition:	O
condition:	O
good	O
mental	O
status:	O
alert,	O
oriented	B-Delirium
x	O
3	O
ambulatory	B-Independently_mobile
status:	O
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
after	O
a	O
procedure	O
called	O
an	O
ERCP.	O
We	O
obtained	O
brushings	O
from	O
your	O
pancreatic	O
duct	O
in	O
attempt	O
to	O
diagnose	O
the	O
cause	O
of	O
the	O
mass	O
in	O
the	O
pancreas.	O
You	O
had	O
a	O
stent	O
placed	O
in	O
this	O
duct	O
and	O
will	O
be	O
contacted	O
by	O
our	O
ERCP	O
team	O
to	O
return	O
to	O
have	O
the	O
stent	O
removed	O
in	O
3	O
weeks.	O
Our	O
ERCP	O
team	O
will	O
also	O
contact	O
you	O
to	O
let	O
you	O
know	O
the	O
results	O
of	O
the	O
pancreatic	O
duct	O
brushing	O
samples.	O
Our	O
cytology	O
laboratory	O
is	O
currently	O
still	O
studying	O
the	O
samples.	O
Please	O
do	O
not	O
use	O
any	O
medicines	O
such	O
as	O
aspirin	O
or	O
ibuprofen	O
for	O
the	O
next	O
5	O
days.	O
Followup	O
Instructions:	O
___	O

